Zeropain

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zeropain

Property Description
Active Ingredient Ketorolac Tromethamine
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Origin Synthetic compound (Phenylacetic acid derivative)
Forms Tablets, Injection, Ophthalmic solution, Nasal spray
Primary Function Potent short-term relief of acute pain

What Type of Medicine is Zeropain and What is its Composition?

Zeropain is the brand name for a potent medication whose active component is Ketorolac Tromethamine, which belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) pharmacological class. This synthetic medicine is chemically classified as a derivative of phenylacetic acid and is highly regarded in medicine for its rapid and effective pain-relieving action. Unlike many commonly known NSAIDs, Ketorolac is a prescription-only medicine characterized by its powerful analgesic properties, and as a single-ingredient product, its composition is focused entirely on delivering the high efficacy of this active substance.

This classification means Zeropain operates by targeting the body's inflammatory process at a chemical level, a mechanism that is distinct from narcotic pain relievers. The medicine is synthesized to specifically inhibit certain enzymes that produce prostaglandins, which are the chemical messengers responsible for causing pain and inflammation. Ketorolac is primarily distinguished by its potent ability to halt prostaglandin production, which is key to its analgesic function. This mechanism is clinically recognized for providing significant symptomatic relief.


How Does Zeropain Differ from Other Pain Relievers?

Zeropain is principally distinguished by its exceptional potency and is reserved for the short-term management of moderate to severe acute pain, often where a non-opioid, prescription-strength solution is necessary. It is used for addressing acute pain states, separating it from therapies used for chronic conditions. The medication provides effective post-operative pain control. While over-the-counter NSAIDs are designed for general, mild discomfort, Zeropain is typically utilized for intense pain following procedures or injuries, providing a vital tool for immediate care. The medication is prepared in multiple dosage forms—including tablets for oral use, a solution for injection for clinical settings, and an ophthalmic solution—allowing medical professionals to select the optimal delivery for the patient's specific need. This versatility in administration route, combined with its high efficacy, ensures that potent analgesic therapy can be precisely tailored to provide swift and substantial relief from acute physical suffering.

Regulatory References

  1. Prostaglandins: Function and Role in Inflammation

What side effects are possible with Zeropain?

Possible side effects and safety information

The safety profile of Zeropain, which contains Ketorolac Tromethamine, is defined by a range of officially documented adverse reactions classified by frequency and the organ system affected. The medication is associated with a risk of serious, dose- and duration-dependent events.


Key Adverse Reaction Categories

The most frequently reported adverse reactions often affect the Gastrointestinal Disorders and Nervous System Disorders organ classes. According to official regulatory documents, effects like headache, nausea, and dyspepsia (indigestion) are frequently classified as Very Common or Common [FDA Label]. Other documented effects are categorized as Uncommon or Rare.

Classification Examples of Effects (Official Sources)
Common Dizziness, somnolence, diarrhea, edema, hypertension.
Rare Acute renal failure, liver failure, anaphylaxis, severe skin reactions.

Serious Adverse Reactions and Safety Constraints

The medication carries a documented risk of Serious Adverse Reactions (SARs) that are potentially fatal. These include gastrointestinal bleeding, ulceration, and perforation, as well as major cardiovascular thrombotic events (such as myocardial infarction and stroke) [EMA SmPC]. These serious events can occur at any time during treatment.

Strict safety constraints dictate that the total combined duration of systemic use (injection and tablet) must not exceed five days for adults, as the risk of SARs increases significantly with longer exposure. Safety considerations also apply to specific groups; the risk of serious gastrointestinal and renal events is officially noted as higher in older adults, and the drug is contraindicated in patients with established moderate to severe renal or hepatic impairment [FDA Label].

This structure ensures the safety profile is communicated with factual emphasis on risks and regulatory limitations.

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding overdose is based strictly on documentation from government health authorities, defining the officially recognized manifestations and emergency actions.

Overdose symptoms are commonly limited to acute gastrointestinal effects, which are generally reported as reversible with supportive care. Documented manifestations include nausea, vomiting, epigastric pain, abdominal pain, lethargy, drowsiness, and hyperventilation. Acute ingestion may be associated with complications such as gastrointestinal bleeding, peptic ulcers, and erosive gastritis.

Mandatory Emergency Action

If an overdose is suspected, seek immediate medical attention, call 911, or contact a Poison Control center. Urgent medical evaluation is required due to the risk of severe, though rare, outcomes. These include documented events such as acute renal failure, hypertension, respiratory depression, and coma.

Treatment and Considerations

Management is based on symptomatic and supportive care, as the official labeling states there is no specific antidote for Ketorolac Tromethamine overdose. Supportive measures such as activated charcoal may be indicated within four hours of ingestion. Dialysis is generally considered ineffective for clearing the drug.

Population-specific overdose notes indicate that the risk of serious adverse events is dose-dependent, and elderly patients or those with renal impairment face an officially documented higher risk for serious complications.

Therapeutic Uses of Zeropain

What Zeropain Treats: Main Uses and Benefits

The medication is generally used for the short-term management of moderate to severe acute pain, often applied in clinical settings for discomfort that follows specific medical events, such as surgical procedures. It helps address symptom clusters that may become intense or disruptive and create noticeable interference with daily stability. The core therapeutic benefit contributes to improved comfort during periods of heightened symptoms by offering supportive symptomatic relief for high-intensity discomfort, and may help patients cope more steadily with symptom fluctuations.

This medication is generally used in clinical settings to manage post-operative pain, post-procedural discomfort, and other acute pain states associated with physical discomfort. It offers symptomatic relief that supports patients during difficult episodes by easing distress and provides supportive symptomatic assistance when symptoms become temporarily overwhelming. This makes it relevant across therapeutic domains where short-term symptomatic assistance is needed for patients experiencing symptoms related to inflammatory or irritative states.

“The primary role of Zeropain is to provide potent, supportive relief for acute discomfort when the symptom load is high.”


Quick Fact: Relief for Acute High-Intensity Pain

Zeropain is applied when symptoms related to physical discomfort intensify, requiring supportive relief that is generally considered relevant for situations involving marked discomfort. The focus is on short-term symptom stabilization during episodes of sudden escalation.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Zeropain (Ketorolac Tromethamine) is intended for use in adults 16 years of age and older and is subject to numerous, strict limitations defined by regulatory agencies. It is not indicated for use in children, in those with minor pain, or for chronic conditions.


Contraindicated Populations (Must Not Use)

This medication is CONTRAINDICATED for use in patients with:

  • Gastrointestinal History: Active peptic ulcer disease, recent GI bleeding or perforation, or a history of these conditions.
  • Renal Impairment: Advanced kidney impairment or risk for renal failure due to volume depletion.
  • Bleeding Risk: Suspected or confirmed bleeding in the brain (cerebrovascular bleeding), hemorrhagic diathesis, or high risk of bleeding.
  • Cardiovascular: Peri-operative pain setting for Coronary Artery Bypass Graft (CABG) surgery.
  • Reproductive Status: In the third trimester of pregnancy, during labor and delivery, or while breastfeeding.
  • Hypersensitivity: Known allergic reactions to Zeropain, aspirin, or other NSAIDs.

Conditional Use and Special Populations

Use is restricted for specific populations who are at greater risk of serious events. Geriatric patients (65 years and older), patients with moderately elevated serum creatinine, or those weighing less than 50 kg (110 lbs) are considered special populations and require a dosage adjustment.

What should I know about interactions with other medicines?

Zeropain (Ketorolac Tromethamine) has officially documented interaction restrictions that are strictly mandated by regulatory authorities. Co-administration is CONTRAINDICATED with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including Aspirin, due to the cumulative risk of serious NSAID-related adverse effects, such as gastrointestinal bleeding and renal toxicity. The combination with Probenecid is also strictly prohibited, as it results in significantly increased Zeropain plasma concentrations and reduced clearance.

Official labeling identifies significant Pharmacodynamic Interactions that increase risk. Co-administration with Anticoagulants (e.g., Warfarin), Antiplatelet Agents, SSRIs, or Corticosteroids increases the risk of bleeding and gastrointestinal ulceration due to additive effects. Zeropain also interacts with medications that affect kidney function, resulting in Exposure Modification. It can increase the plasma levels of both Lithium and Methotrexate by decreasing their renal clearance. Furthermore, it may diminish the antihypertensive effect and increase the risk of renal impairment when combined with ACE Inhibitors or ARBs.

Non-Medicinal Substance Interactions include an increased risk of gastrointestinal bleeding when Zeropain is combined with Alcohol (Ethanol). A fatty meal may delay or reduce the absorption of the oral formulation. For specific populations, regulatory documents note that clearance may be slower in elderly patients (≥65), which increases sensitivity to dose-related adverse effects and interactions. The total duration of administration across all formulations must not exceed five days.

Mechanism of Action

Zeropain, whose active pharmaceutical ingredient is ketorolac tromethamine, functions as a non-steroidal anti-inflammatory drug (NSAID) with a primary mechanism targeting the cyclooxygenase (COX) enzyme system. It acts as a non-selective inhibitor of both the COX-1 and COX-2 isoforms.

This inhibitory interaction prevents the COX enzymes from catalyzing the conversion of arachidonic acid into prostaglandins and other eicosanoids. Prostaglandins are key lipid mediators in local cellular responses. The resulting molecular pathway interruption leads to a significant reduction in the peripheral synthesis and release of prostaglandins at target tissues.

The downstream cascade primarily involves the modulation of afferent neuronal sensitization. By reducing prostaglandin concentration, Zeropain diminishes the activation of peripheral nociceptors and their sensitivity to algesic stimuli. The system-level physiological consequence is the functional inhibition of peripheral pain signal transduction to the central nervous system.

Dosage and Administration Information

Zeropain is an analgesic, generally belonging to the non-steroidal anti-inflammatory drug (NSAID) class, and is indicated for the short-term management of moderate to severe acute pain. The specific usage instructions depend on the formulation (e.g., tablet, injection, or topical) and the active ingredient, which may be ketorolac, diclofenac, or a combination.

General Oral Administration

For oral forms, the tablet must be swallowed whole with a glass of water. It should not be crushed, chewed, or broken, as this can affect the controlled release of the medication or increase the risk of gastrointestinal adverse events. Zeropain can generally be taken with or after food to help minimize potential stomach irritation, a common consideration for NSAIDs.

Dosage and Duration Guidelines

Adherence to the prescribed dosage is critical. For formulations containing ketorolac, the total duration of treatment, encompassing both injection and tablet forms, is typically limited to a maximum of 5 days to mitigate the risk of serious side effects. For oral dosage (e.g., 10 mg), the recommended frequency is often every 4–6 hours, with the total daily dose not exceeding 40 mg. Taking the lowest effective dose for the shortest period required to control symptoms is advised for all NSAIDs.

Consult a healthcare professional immediately if you suspect an overdose or experience persistent, bothersome side effects such as nausea, stomach pain, or heartburn.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zeropain (Ketorolac Tromethamine)


Evidence for Short-Term Management of Moderate to Severe Acute Pain

Zeropain was studied in research exploring the short-term management of acute, high-intensity pain in adult populations. The research landscape is characterized primarily by Randomized Controlled Trials (RCTs) and systematic reviews. This research was evaluated in pain that arises from various causes, such as trauma or surgical injury, which are often conditions associated with periods of heightened symptoms.

In these studies, researchers monitored outcomes related to physical discomfort, often by measuring symptom intensity or variability over defined, short-term time intervals following administration. Findings from these trials describe patterns observed in the studies regarding patient-reported outcomes describing perceived discomfort and the time needed for patients to report a perception of relief. Furthermore, studies sometimes monitored the patient's need for supplementary pain medication.

Evidence for Post-Operative Pain Control

Research has also evaluated Zeropain for the management of pain that follows surgical procedures, which are often conditions associated with acute or disruptive episodes. The evidence in this area derives from numerous Randomized Controlled Trials (RCTs) conducted in controlled clinical settings. These trials typically compared Zeropain to placebo, or to other medications, often as part of a multi-modal approach to managing outcomes related to physical discomfort.

The key research examined not only pain intensity scores in the hours and days immediately following surgery but also the amount of supplementary pain medication administered to patients. Studies explored whether use of Zeropain was associated with a change in the amount of supplementary pain medication administered to patients during the recovery period.

Gaps and Areas of Uncertainty in the Research

The research base for Zeropain focuses predominantly on exploring short-term symptom changes. Due to this focus, studies were not designed to monitor outcomes over extended periods, meaning the long-term effects are not fully established. Data for certain groups remain insufficient; although some studies have included special populations like older adults and children, comparative evidence is lacking for many subgroups, and certainty remains low in some instances.

Key Studies & References Comparison of Ketorolac at 3 Doses in Children With Acute Pain: Protocol for A Randomized Controlled Trial (KETODOSE trial concept)

Frequently Asked Questions (FAQ)

Common questions about Zeropain (FAQ)


Q: How quickly do people usually start to feel the effects of Zeropain?

Official information derived from pharmacokinetic studies, which examine how the drug moves through the body, indicates that the peak analgesic effects of Zeropain are generally reached within one to two hours following administration. This timeframe is consistent with when the maximum concentration and resulting pain-relieving effect are commonly observed.

Q: What is the typical length of time the effects of Zeropain last?

The duration of the pain-relieving effect for the active ingredient is commonly described in regulatory summaries as persisting for approximately four to six hours. This timeframe assists in understanding the potential duration of the drug’s pharmacological activity.

Q: Is it necessary to take Zeropain with food?

Patient information notes that Zeropain can be taken with food or a liquid antacid to help lessen stomach upset, a common consideration for this class of medicine. However, official documentation does not describe taking it with food as a mandatory requirement.

Q: Can Zeropain be crushed or split for easier use?

Official administration guidelines for the oral tablet state that it must be swallowed whole and should not be crushed, chewed, or broken. This requirement is in place because altering the tablet can affect how the medicine is absorbed and may increase the risk of adverse gastrointestinal side effects.

Q: Is it normal to feel a mild headache when first starting Zeropain?

According to official drug documents, headache is listed as a very common or common adverse reaction associated with the use of Zeropain. The classification of an effect as 'common' means it is frequently observed in patients using the medication.

Q: Is Zeropain known to cause any skin reactions or rashes?

Yes, official documentation lists several adverse reactions affecting the skin, including maculopapular rash, itching (pruritus), hives (urticaria), and sweating. In rare instances, more severe skin conditions, such as bullous reactions, have been documented.

Q: Is Zeropain the same as [Name of common alternative drug]?

Zeropain's active ingredient, ketorolac tromethamine, is classified as a potent, prescription-only Nonsteroidal Anti-inflammatory Drug (NSAID). Its mechanism of action operates differently than that of narcotic pain relievers. The medication is specifically reserved for managing moderately severe acute pain.

Q: What makes Zeropain different from other analgesics in its class?

Official labeling distinguishes Zeropain by its use restriction. It is principally reserved for the short-term management (a maximum of five days) of moderately severe acute pain, often where strong, short-term pain relief is necessary. This focus separates it from many other NSAIDs.

Q: How does Zeropain's efficacy compare in official trials to a placebo?

Studies, including randomized controlled trials, have described Zeropain as being more effective than placebo for the symptomatic relief of moderate to severe pain in adult populations. This finding describes the medicine's pharmacological action in the context of acute pain management.

Q: Can Zeropain be taken by people who have high blood pressure?

Regulatory labeling advises that Zeropain, like other NSAIDs, should be used with caution in patients with pre-existing high blood pressure (hypertension). This is because the medication may worsen the condition or may potentially reduce the effectiveness of certain prescribed blood pressure medications. Any use in patients with high blood pressure is subject to professional review due to this potential interaction.

Q: Are there any known issues with drinking coffee while taking Zeropain?

The official product labeling does not typically list a specific warning for consuming coffee or caffeine. However, some research has examined the combination and found that, in animal studies, researchers have noted an amplification of effects that may increase the risk of adverse renal events was observed in animal studies.

Q: Can people who are taking common vitamins or supplements use Zeropain?

While regulatory documents specifically list interactions with many prescription medicines, they do not comprehensively detail every vitamin or supplement. Patient information consistently advises that a healthcare professional be informed about all products being used, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Q: Has there been long-term research on the effects of Zeropain?

The research base for Zeropain is predominantly focused on short-term symptom management, which aligns with its maximum approved duration of five days. Due to this focus, official information states that the potential long-term effects of the medication are not fully established.

Q: What should a person know about stopping Zeropain after short-term use?

Official guidelines advise that Zeropain should be switched to an alternate analgesic therapy as soon as clinically possible. Furthermore, studies on the active ingredient have shown no evidence that short-term therapy results in the development of physical dependence.

Q: Are there documented cases of people developing a tolerance to Zeropain?

The active ingredient in Zeropain is chemically distinct from opioid agonists and is not associated with physical dependence. Official reports on the active ingredient do not document the development of physical tolerance.

Q: Is Zeropain known to affect blood sugar levels?

Drug interaction information notes that combining the active ingredient in Zeropain with insulin or certain other diabetes medications may increase the risk of low blood sugar (hypoglycemia). Any use in patients taking these medications is subject to professional review due to this potential interaction.

Q: Are there any restrictions on strenuous activity while taking Zeropain?

Official labeling notes that common side effects include dizziness and somnolence (drowsiness). Therefore, activities that require complete mental alertness and physical coordination, including strenuous activity, may be affected by these common side effects.

Q: Do studies suggest Zeropain has any known effects on mood or anxiety?

Yes, official documentation lists several psychiatric adverse reactions associated with the medication. These reactions include, but are not limited to, abnormal thinking, anxiety, depression, euphoria, and nervousness. These effects are based on reports from clinical use.

How should Zeropain be stored and disposed of?

How to Store and Dispose of Zeropain (Ketorolac Tromethamine)

Official regulatory information outlines specific conditions for the storage, handling, and disposal of Zeropain.

Storage and Handling

Zeropain must be stored at Controlled Room Temperature (typically 15 C to 30 C) and kept away from excess heat. The medication must be protected from light and moisture and should remain in a tightly closed, light-resistant container. Liquid formulations, such as the injection, must not be frozen or refrigerated and require immediate use after opening or any unused portion must be discarded. The medicine must be kept out of the reach of children.

Disposal Requirements

Dispose of any unused or expired Zeropain strictly according to local and national requirements. This typically means utilizing an authorized drug take-back program or following guidelines for non-hazardous pharmaceutical waste. The product should not be disposed of in drains or released into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zeropain found in:

A-Z Index: